TenNor Therapeutics is a clinical-stage company in Suzhou, China, focused on discovery and development of differentiated new drug products against bacterial infection and metabolism-related diseases. It possesses a multi-targeting drug conjugate technology platform and strong new drug development portfolio with global IP protection. Several products are currently in late-stage clinical development targeting H. pylori infection, medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company raised over RMB300M in a Series E financing; backers included AMR Action Fund, Zhongshan Venture Capital and other existing investors. Proceeds will support development and the pursuit of regulatory approval in China for rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. Led by founder and CEO Dr. Zhenkun Ma, TenNor says it is committed to addressing unmet needs and providing safe, effective therapies for patients in China and globally. TenNor Therapeutics is a Suzhou, China–based clinical-stage company focused on developing dual-acting antibiotics. Its lead candidate is TNP-2092, an oral capsule designed as a locally acting gastrointestinal antibiotic with potential to improve treatment of Helicobacter pylori and other gastrointestinal bacterial infections. The compound is currently in early-stage clinical development. TenNor intends to use the Series B proceeds to advance TNP-2092 into Phase III trials, move a second product to clinical proof-of-concept, and advance a third into Phase I. Founded in 2013 in BioBAY by Dr. Zhenkun Ma, the company is advancing several dual-acting molecules through preclinical and clinical stages. TenNor has acquired patents and other assets from Cumbre IP Venture and patents from the TB Alliance and raised $25M in this Series B.

Total raised

$67M

Funding rounds

2

Latest round

Series E

Latest activity

Oct 2024